Preventive Therapy in Pediatric Migraine

DRUG	MAINTENANCE DOSAGE ^a	SIDE EFFECTS	
ANTIEPILEPTIC			
Divalproex sodium	10-45 mg/kg/day	Weight gain, hepatotoxicity, teratogenicity	
Topiramate ^b	1-2 mg/kg/day; alternative dosing is 100 mg/day	Paresthesias, weight loss, kidney stones	
Levetiracetam	20-40 mg/kg/day	Behavioral changes, irritability	
Zonisamide	3-5 mg/kg/day	Behavioral changes, sedation	
BETA-BLOCKER			
Propanolol	1 mg/kg/day	Fatigue, depression, exercise intolerance, asthma exacerbation	
CALCIUM CHANNEL BLOCKER			
Flunarizine°	5 mg/day	Sedation, weight gain	
ANTIDEPRESSANTS (TRICYCLICS)		
Amitriptyline	1 mg/kg/day divided twice daily	Sedation, weight gain, cardiac effects (Q-T prolongation)	
Trazadone	1 mg/kg/day	Sedation, dry mouth, visual blurriness	
ANTIHISTAMINE			
Cyproheptadine	0.2-0.4 mg/kg/day	Sedation, weight gain	
NUTRACEUTICAL			
Magnesium oxide	9 mg/kg/day; alternative dosing is 400 mg/day	Gastrointestinal (diarrhea)	
Coenzyme Q10	1-3 mg/kg/day; alternative dosing is 100 mg/day	Gastrointestinal, anorexia, rash	

^aDosage data were obtained from available pediatric studies or extrapolated from adult studies.9-11 Titrate up to maintenance dosing. ^bApproved by the US Food and Drug Administration for episodic migraine preventive therapy in adolescents. ^cNot available in the United States.

Adapted from: Khrizman M, Pakalnis A. Management of Pediatric Migraine: Current Therapies. Pediatric Annals. 2018 Feb 1;47(2): e55-e60.





Triptans for Acute Treatment of Pediatric Migraine

DRUG	ADMINISTRATION	USUAL DOSAGE ^a	HALF-LIFE (H)	
FAST-ACTING				
Almotriptan	Oral⁵	6.25 mg; 12.5 mg	3-4	
Eletriptan	Oral	20 mg; 40 mg	4	
Rizatriptan	Oral⁵	5 mg (20-39 kg); 10 mg (>40 kg)	2-3	
Zolmitriptan	Oral Nasal ^b	2.5 mg; 5mg 5 mg	3	
Sumatriptan	Oral Nasal Subcutaneous	25 mg; 50 mg; 100 mg 5 mg; 20 mg 0.06 mg/kg; 4 mg; 6 mg	3	
Sumatriptan and naproxen sodium concentration	Oral ^b	10/65 mg; 85/500 mg	3	
LONG-ACTING				
Frovatriptan ^c	Oral	2.5 mg	26	
Naratriptan ^c	Oral	2.5 mg	6	

^aDosage data were obtained from available pediatric studies or extrapolated from adult studies.3,5,6

^bFormulation approved in pediatric migraine: almotriptan, age 12-17 years; rizatriptan, age 6-17 years, zolmitriptan, age 12-17 years; sumatriptan and naproxen combination, age 12-17 years.

^cNo studies in children or adolescents have been reported.

Adapted from: Khrizman M, Pakalnis A. Management of Pediatric Migraine: Current Therapies. Pediatric Annals. 2018 Feb 1;47(2): e55-e60.

Referrals and Consultations

Online: NationwideChildrens.org Phone: (614) 722-4625 Physician Direct Connect Line for 24-hour urgent physician consultations: (614) 355-0221 or (877) 355-0221



